^
Association details:
| Biomarker: | HLA-DRB1-MET fusion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tepotinib efficacy in an NSCLC patient with brain metastasis harboring an HLA-DRB1-MET gene fusion
Published date:
07/27/2020
Excerpt:
In this study, we present the case of a 41-year old woman with advanced NSCLC harboring an HLA-DRB1-MET gene fusion. The patient was offered successively two different MET multikinase inhibitors crizotinib and cabozantinib and the selective inhibitor, tepotinib. Each time, including under tepotinib, the patient experienced rapid and complete responses associated with a tremendous improvement in her physical function.
DOI:
10.1634/theoncologist.2020-0502
